# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹403 Cr** Q4 FY26 (+12% YoY) · **₹1,454 Cr** FY26 (+1.7% YoY) * **EBITDA:** **₹102 Cr** Q4 FY26 (+50% YoY) · **₹294 Cr** FY26 (+11% YoY) * **EBITDA Margin:** **25%** Q4 FY26 (+600 bps YoY) · **20%** FY26 (+100 bps YoY) * **PAT:** **₹65 Cr** Q4 FY26 (+62.5% YoY) · **₹169 Cr** FY26 (+7% YoY) * **EPS (Diluted):** **₹19.99** Q4 FY26 (+110% QoQ) ## B. Margins & Profitability * **Operational Efficiency:** Significant quarterly margin expansion driven by stable input costs, superior operating leverage, and an optimized product mix. * **Profitability Drivers:** Bottom-line growth supported by robust customer demand and disciplined inventory management; management expects to sustain these levels as new capacities come online. * **Future Guidance:** Management targets a **22% EBITDA margin** on a specific chemical product line, assuming an **80% utilization rate** on **100,000 tons** of capacity. * **Accounting Nuance:** Current quarterly figures may not serve as a steady-state benchmark due to the **capitalization of plant modifications** versus the expensing of standard repairs. ## C. Balance Sheet & Cash Flow * **Capital Structure:** Maintained a debt-free status on a standalone basis, though consolidated debt reached **₹133 Cr** to fund aggressive expansion. * **Net Worth & Liquidity:** Consolidated net worth climbed to **₹2,152 Cr**, supported by healthy internal accruals despite heavy reinvestment. * **Cash Allocation:** Generated **₹184 Cr** in operating cash flow, which was entirely redeployed into growth projects, resulting in a negative investing cash flow of **₹344 Cr**. --- # 2. Manufacturing & Capacity ## A. Key Figures * **Total Standalone Capacity:** **293,000 MT** * **Current Utilization:** **35% to 40%** overall company rate · **20% to 25%** battery chemical unit * **DME Project Specs:** **100,000 MT** capacity · **30% to 40%** FY27 target utilization * **New Project Capacities:** **5,000 TPA** N-Methyl Morpholine (NMM) * **Production Run Rate:** **25,000 tonnes** per quarter (raw material secured) ## B. Project Commissioning & Timeline * **FY27 Commissioning Cluster:** Major projects including Dimethyl Ether (DME), N-Methyl Morpholine (NMM), and an improved Acetonitrile (ACN) plant are slated for rollout throughout FY27. * **Value-Added Expansion:** The Unit-I brownfield project, focusing on EDA-based products (DETA, TETA, PIP, etc.), is on track for a **H1 FY27** launch. * **Greenfield Progress:** Construction is underway at Unit-II for HCN and EDTA lines, with commissioning expected in **Q4 FY27**. * **Subsidiary Normalization:** Balaji Specialty Chemicals is undergoing modifications; management expects normalized performance visibility from **Q3 onwards** following nearly a year of plant adjustments. ## C. Utilization Dynamics & Market Outlook * **Utilization Headwinds:** Current low absorption is tied to sluggish demand in DMF, butylamines, and battery chemicals, as the domestic battery sector has yet to scale. * **Battery Chemical Pivot:** While waiting for the battery sector to ramp up (expected **April**), the unit is currently servicing the agro and pharma sectors at reduced capacity. * **DME Scaling Strategy:** Despite current infrastructure hurdles, DME utilization is projected to reach **80% to 90%** long-term as it penetrates the aerosol and industrial baking markets. * **Operational Constraints:** Full DME scaling is temporarily pending government road transport permissions, anticipated within **one month**. ## D. Expansion Strategy & Infrastructure * **Strategic Diversification:** Management is intentionally bypassing capacity hikes for existing products in favor of **new product lines** to drive future growth despite current sub-optimal utilization. * **Self-Funded Growth:** Major FY27 projects, including the ACN and NMM plants, are being financed entirely through **internal accruals**. * **Stakeholder Engagement:** A site visit is planned for **late May to mid-June 2026** to demonstrate progress on greenfield and brownfield machinery installations. --- # 3. Product & Segment Performance ## A. Key Figures * **New Product Pricing:** **₹240** Acetonitrile · **₹250–₹300** N-Methylmorpholine (NMM) · **₹100–₹120** Dimethyl Ether * **Trial Volume:** **100 cylinders** (500 kg each) dispatched to bulk consumers for quality validation ## B. Specialty Chemicals & Import Substitution * **Strategic Portfolio Expansion:** Continued ramp-up of high-value electronic-grade DMC and DMF to anchor long-term growth. * **First-to-Market Advantage:** Focus on high-demand derivatives like TETA, TEPA, AEEA, and AEP; notably, **TETA** currently has no other domestic manufacturer in India. * **Indigenous Technology Focus:** Prioritizing import substitution through proprietary manufacturing technology to strengthen the core amines and specialty platforms. ## C. New Product Launch & Growth Drivers * **FY25-26 Growth Catalysts:** Future momentum is tied to the commercialization of Acetonitrile, NMM, and Dimethyl Ether, with the latter two being produced domestically for the first time. * **Greenfield Expansion:** Initiating projects for Hydrogen Cyanide and Sodium Cyanide to capture robust domestic and international demand. * **Technology Upgrades:** Upgraded production technology for Acetonitrile to better align the specialty chemicals platform with future market requirements. ## D. Battery Chemicals * **Sector Tailwinds:** Anticipated entry into the battery industry supply chain within the current fiscal, with operations expected to stabilize by the next financial year. --- # 4. Capital Allocation ## A. Key Figures * **Consolidated Capex:** **₹275 Cr – ₹290 Cr** Current Year Estimate * **Subsidiary Investment (BSC):** **₹750 Cr** Total Phased Expansion · **₹350 Cr – ₹400 Cr** Phase 1 Budget * **Standalone Residual Capex:** **₹20 Cr** Remaining for DME, NMM, and ACN ## B. Capex Execution & Strategy * **Standalone Completion:** Core projects for DME, NMM, and ACN are nearing finalization, with the vast majority of equipment advances already settled. * **Strategic Subsidiary Expansion:** Balaji Specialty Chemicals (BSC) is executing a massive phased expansion, benefiting from **Mega Project status** and government incentives in Maharashtra. ## C. Subsidiary Governance & IPO * **IPO Deferral:** The public listing for BSC is postponed as management prioritizes bringing the full planned product portfolio to market before seeking a valuation event. * **Stake Consolidation:** Increasing the current **51%** stake in BSC remains a future consideration, contingent upon dual-board approvals and shareholder alignment at an appropriate juncture. --- # 5. Demand & Pricing Trends ## A. Key Figures * **Consolidated Sales Volume:** **27,341 MT** Q4 FY26 Total * **Volume Mix:** **7,746 MT** Amines · **8,935 MT** Amine Derivatives · **10,660 MT** Specialty Chemicals * **Product Pricing:** **~300** Q4 Average · **270 to 280** Current Range · **400** Historical Peak * **Client Concentration:** **15% to 20%** DMA HCL outflow to single Metformin manufacturer ## B. End-user Demand & Market Dynamics * **Sector Resilience:** Consistent demand across core pharma, agrochemical, and solvent verticals continues to validate the integrated manufacturing model. * **EV Battery Traction:** Initial commercial orders of **100 to 150 tons** secured; buyers are currently processing these into electrolytes for export as domestic infrastructure matures. * **Strategic Diversification:** Future growth pivot targeting high-value applications in Water Treatment, Refineries, and EV Battery Chemicals. ## C. Pricing & Competitive Positioning * **Pricing Correction:** Average realizations have softened from Q4 levels toward a lower current range, remaining well below historical peaks. * **Defensive Moat:** Despite backward integration by a major client, the company maintains its supply share due to a **superior cost of production** advantage. * **DME Project Economics:** High profitability anticipated for Dimethyl Ether (DME) driven by a **INR 1,000** hike in cylinder prices and India's high LPG import dependency (**25%-40%**). ## D. Operational Outlook * **DME Commercialization:** Prospective buyer interest matches total capacity; final sales are contingent upon pending **road transport permissions** and sample approvals. --- # 6. Risks & External Factors ## A. Key Figures * **Raw Material Inflation:** **2x to 3x** regular levels for core inputs · **~3x** normal price for Monoethanolamine * **Procurement Frequency:** **3 to 4 days** for Methanol (vs. previous monthly cycle) * Regulatory Deadlines: End of June expiration for current duty-free government orders ## B. Raw Material Volatility * **Input Cost Pressure:** Unprecedented price surges in key feedstocks have triggered global plant shutdowns and compressed current EBITDA spreads. * **Strategic Procurement:** Management has shifted to high-frequency purchasing cycles for volatile inputs like methanol to mitigate pricing risks. * **Margin Uncertainty:** While current realizations for Dimethyl Ether remain stable, future predictability is hampered by extreme feedstock price swings. ## C. Geopolitical Impact * **Operational Resilience:** Prudent inventory planning successfully neutralized a brief production disruption in **March 2026** caused by external tensions. * **Dynamic Pricing:** Heightened geopolitical instability has forced a shift to near-daily price adjustments for both raw materials and finished goods to protect margins. ## D. Regulatory & Anti-dumping * **Import Protection:** Dimethyl Ether (DME) faces negligible dumping risk from China due to the logistical complexities of transporting the product in gas form. * **Duty Headwinds:** Progress on anti-dumping cases for Ethylenediamine (EDA) is currently stalled by government mandates keeping certain products duty-free through mid-2026. * **Regulatory Outlook:** Management anticipates a clearer trajectory for pending anti-dumping filings once current government exemptions expire at the end of the quarter. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Target:** **₹2,000 Cr** by FY28 (Balaji Speciality Chemicals & DME) · **₹3,000 Cr** by FY28 (Consolidated) * **Volume Growth Guidance:** **10% to 15%** current fiscal · **20% to 30%** next financial year · **25% to 30%** by end of FY27 * **EBITDA Margin:** **22% to 23%** sustainable range on total sales ## B. Revenue Targets * **Strategic Growth Drivers:** Long-term revenue targets are anchored by contributions from Balaji Speciality Chemicals and the commercialization of Dimethyl Ether (DME). * **Phased Contribution:** Top-line impact from new products is back-ended to the **second half of the fiscal year**, pending customer trials and transport permissions. * **Government Engagement:** Management expects to commence DME supplies to the government starting in **Q1**, supporting the broader FY28 scaling objectives. ## C. Volume & Margin Outlook * **Capacity Ramp-up:** Robust volume expansion is predicated on the commissioning of three key plants: Acetonitrile, DME, and N-Methylmorpholine (NMM). * **Operational Efficiency:** Growth targets for FY27 rely on improved capacity utilization across both legacy and new product lines. * **Profitability Floor:** Management maintains a confident margin outlook, projecting sustainable double-digit EBITDA performance despite raw material and geopolitical volatility.